# Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

> **NCT00255008** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 121 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** peginterferon alfa-2b
- **DRUG:** ribavirin
- **BIOLOGICAL:** peginterferon alfa-2b
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00255008
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255008, "Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00255008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*